<unk>  (LS-SCLC) is a type of<unk> <unk>  lung cancer (SCLC) that is confined to an area which is<unk>  enough to be encompassed within a radiation portal. This generally includes cancer to one side of the lung and those might have reached the lymph nodes on the same side of the lung. 33% patients with<unk> <unk>  lung cancer are diagnosed with<unk>  when it is first found. Common symptoms include but are not<unk>  to persistent cough, chest pain, rust-coloured sputum, shortness of breath, fatigue, weight loss, wheezing, hoarseness and recurrent respiratory tract infections such as pneumonia and bronchitis. Nervous system problems, Cushing syndrome and SIADH (syndrome of inappropriate anti-diuretic hormone) can also be associated with<unk> <unk>  lung cancer. Unlike extensive-stage<unk> <unk>  lung cancer,<unk>  is potentially curable. Standard treatments consist of surgery, platinum-based combination chemotherapy, thoracic irradiation, and prophylactic cranial irradiation. Patient five-year survival rate has significantly increased from 1% with surgery to 26% after the application of combination chemotherapy.
Limited-stage small cell lung carcinoma
Minimally invasive adenocarcinoma of the lung
Salivary gland–like carcinoma of the lung
EML4-ALK positive lung cancer
Combined small-cell lung carcinoma
Atypical pulmonary carcinoid tumour
Epithelial-myoepithelial carcinoma of the lung
Large cell neuroendocrine carcinoma of the lung